Cipla Chief Calls For Invigorating Focus On Repurposed Drugs
Executive Summary
Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
You may also be interested in...
Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?
A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.
‘Champions’ To Lead European Drug Repurposing Project
Work is under way on a new European procedure for repurposing off-patent medicines for new uses. It would mainly be used for active substances where there was more than one marketing authorization holder and the relevant data were generated by a third party.
Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug
Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.